Nuclear Medicine Market Regional Trends and Market Share Forecast 2026–2034

`

The global nuclear medicine market size 2026 was valued at USD 11.77 billion in 2025 and is projected to grow from USD 13.72 billion in 2026 to USD 66.11 billion by 2034, at a remarkable CAGR of 19.90% during the forecast period. Nuclear medicine refers to pharmaceutical drugs containing radioactive formulations of chemical elements (radioisotopes), used for both therapeutic and diagnostic procedures — from imaging organs such as the brain, heart, bone, and kidneys to treating various forms of cancer.

Key Market Drivers

1. Robust Therapeutic Radiopharmaceutical Pipelines Therapeutic radiopharmaceuticals are increasingly preferred by healthcare professionals due to their precision — they act exclusively against malignant cells while leaving healthy tissue unharmed. According to the National Institute for Health Research (NIHR), the majority (62%) of identified radiopharmaceuticals were in Phase 2 development, with nearly 23% in Phase 3 clinical trials, signaling a strong innovation pipeline.
2. New Diagnostic Product Launches Diagnostic radiopharmaceuticals remain in high demand, particularly for PET and SPECT imaging procedures. Regulatory approvals continue to expand the market — in March 2024, the UK's MHRA approved piflufolastat (18F) (Pylclari) by Curium as a diagnostic tool for prostate cancer.
3. AI Integration in Radiopharmaceutical Development Artificial intelligence is emerging as a transformative trend, enhancing accuracy in imaging and enabling earlier disease detection. AI algorithms can process extensive datasets to uncover subtle anomalies, improving lesion detection and disease staging when combined with radiopharmaceuticals.
4. Rising Chronic Disease Prevalence The growing global burden of cancers, cardiovascular diseases, and neurological disorders is driving the need for advanced diagnostic and therapeutic nuclear medicine solutions.

Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/nuclear-medicine-radiopharmaceuticals-market-101812

Market Segmentation

By Type

• Diagnostics dominated the market with a 50.14% share in 2026, driven largely by PET/PET-CT imaging in oncology and cardiology. Sub-segments include PET radiopharmaceuticals (FDG-PET/18F, 68Ga, 68Cu, 11C) and SPECT radiopharmaceuticals (Technetium-99m, Iodine-123, Xenon-133, Thallium-201).
• Therapeutics is projected to register the highest CAGR during the forecast period, with key isotopes including Ra-223, Lu-177, I-131, Y-90, and Sm-153.

By Application

• Oncology led the market with a 61.58% share in 2026 and is also expected to grow at the highest CAGR, driven by increasing cancer prevalence and the use of radiopharmaceuticals for both diagnosis and treatment.
• Cardiology holds a significant share owing to the widespread adoption of these products for diagnosing coronary heart disease.
• Neurology is growing steadily, with products like flortaucipir F18 (approved by the FDA in 2020) used in PET imaging for Alzheimer's disease diagnosis.

By End User

• Hospitals & Clinics dominated with a 58.01% share in 2026. Over 10,000 hospitals globally use medical radioisotopes, with ~90% of procedures being diagnostic, according to the World Nuclear Association.
• Diagnostic Centers held the second-largest share, supported by a large installed base of PET and SPECT equipment.

Regional Insights

Region	2025 Market Value	Market Share
North America	USD 6.20 billion	52.70%
Asia Pacific	USD 2.23 billion	18.90%
Europe	USD 2.21 billion	18.79%
Latin America	USD 0.69 billion	5.85%
Middle East & Africa	USD 0.44 billion	3.75%

North America leads due to strong innovation, high adoption of diagnostic and therapeutic radiopharmaceuticals, and favorable reimbursement environments. The U.S. market alone is projected to reach USD 6.81 billion by 2026.

Asia Pacific is the fastest-growing region, driven by improving healthcare infrastructure, increasing patient populations, and the growing presence of key market players in countries like China, Japan, and India.

Market Restraints

Competition from alternative imaging modalities — particularly MRI and CT scanners — poses a key challenge. MRI scans do not expose patients to radiation, and PET scans have traditionally been more expensive. Additionally, not all PET drugs are covered by Medicare in the U.S., limiting reimbursement and constraining procedure volumes.

Key Industry Players

The competitive landscape is semi-consolidated, with leading players including:

• Novartis AG – Strong portfolio following its 2018 acquisition of Advanced Accelerator Applications; received FDA approval in January 2024 for large-scale Pluvicto (Lu-177) manufacturing.
• Lantheus Holdings, Inc. – Active in strategic agreements; partnered with Perspective Therapeutics for alpha therapy in neuroendocrine tumors.
• GE HealthCare, Bayer AG, Curium, Cardinal Health, Jubilant Pharmova Limited

Notable 2024 developments include Curium's acquisition of Eczacıbaşı-Monrol Nuclear Products and Bayer AG's supply agreement with Ionetix Corporation for actinium-225.

Conclusion

The global nuclear medicine market is on a strong growth trajectory, fueled by an expanding pipeline of therapeutic radiopharmaceuticals, rising disease burden, AI-driven innovation, and supportive regulatory environments. With a projected market value of USD 66.11 billion by 2034, nuclear medicine is poised to become a cornerstone of modern precision medicine.

`